HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA distinguishes supplements from medical foods; super fruits are not drugs, FA explains; Sunland resumes production; Bayer voluntarily nixes Alka-Seltzer claims; FDA cites inflammation as drug claim; three Florida supplement makers warned for drug claims; and FDA warns Michigan e-commerce firm on claims.

You may also be interested in...



FDA Suspension Authority Limits Peanut Recall, But FSMA Remains Grounded

In a series of interviews, food safety experts weigh in on why the food and nutritional products industry still has work to do with the Food Safety Modernization Act not yet implemented, as illustrated by the recent salmonella contamination of peanut ingredients from Sunland Inc.

Bayer Alka-Seltzer Plus Ad Modifications Not Sufficient, NAD Decides

Bayer has assured the National Advertising Division of the Council of Better Business Bureaus it immediately discontinued certain parity claims made for Alka-Seltzer Plus Cold Medicine after NAD decided the modified advertising still was problematic.

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Topics

Related Companies

UsernamePublicRestriction

Register

RS124248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel